NCT02594254View on ClinicalTrials.gov

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

September 30, 2016

Conditions
Dental Caries
Interventions
DRUG

C16G2 Gel

Antimicrobial peptide

OTHER

Placebo

Placebo

Trial Locations (10)

10010

New York University College of Dentistry, New York

19104

University of Pennsylvania School of Dental Medicine, Philadelphia

27834

East Carolina University, Greenville

46202

Indiana University School of Dentistry, Indianapolis

59901

John F. Pittaway, DMD, Kalispell

Plaza West II Dental Group, Kalispell

75063

Anthony Henegar, DDS, PA, Irving

75246

Texas Baylor College of Dentistry, Dallas

91932

Imperial Beach Family Dentistry, Imperial Beach

02111

Tufts University, Boston

Sponsors
All Listed Sponsors
collaborator

Vantage Data Designs, Inc.

INDUSTRY

collaborator

SynteractHCR

INDUSTRY

collaborator

Agility Clinical, Inc.

INDUSTRY

lead

Armata Pharmaceuticals, Inc.

INDUSTRY